EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC

James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi iD, Enriqueta Felip, Alexander I Spira, Nicolas Girard, Yu Jung Kim, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip und 45 weitere

New England Journal of Medicine · 30.10.2025 · 393 (17) · 1681-1693

DOI: 10.1056/nejmoa2503001 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 30.10.2025. Verfasst von James Chih-Hsin Yang und 56 weiteren Autor:innen. Beteiligte Einrichtung: National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Acrylamides, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 163-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Janssen Research & Development, LLC, a Johnson & Johnson company..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsTyrosine Kinase InhibitorsAgedFemaleHumansMaleMiddle AgedAniline CompoundsErbB ReceptorsKaplan-Meier EstimateMutationProtein Kinase InhibitorsAntibodies, BispecificIndolesPyrimidinesSurvival RateInfusions, IntravenousProgression-Free SurvivalMorpholinesPyrazoles

Substanzen

AcrylamidesamivantamabAniline CompoundsEGFR protein, humanErbB ReceptorsosimertinibProtein Kinase InhibitorslazertinibTyrosine Kinase InhibitorsAntibodies, Bispecific

Autor:innen und Institutionen

  • National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona.
  • Virginia Cancer Specialists, Fairfax.
  • Institut Curie, Paris.

ORCID-Profile: Hidetoshi Hayashi, Benjamin Besse, Antonio Passaro, Jaydeep Mehta, Byoung Chul Cho

Förderung

  • Janssen Research & Development, LLC, a Johnson & Johnson company.

Zitieren

APA

Yang, J. C., Lu, S., Hayashi, H., Felip, E., Spira, A. I., Girard, N., Kim, Y. J., Lee, S. H., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Mourão Dias, J., Besse, B., Passaro, A., Lee, K. H., Xiong, H., How, S. H., …, & MARIPOSA Investigators (2025). Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine, 393(17), 1681-1693. https://doi.org/10.1056/nejmoa2503001

Vancouver

Yang JC, Lu S, Hayashi H, Felip E, Spira AI, Girard N, et al. Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. 2025;393(17):1681-1693. doi:10.1056/nejmoa2503001

BibTeX
@article{Yang2025,
  author = {Yang, James Chih-Hsin and Lu, Shun and Hayashi, Hidetoshi and Felip, Enriqueta and Spira, Alexander I and Girard, Nicolas and Kim, Yu Jung and Lee, Se-Hoon and Ostapenko, Yurii and Danchaivijitr, Pongwut and Liu, Baogang and Alip, Adlinda and Korbenfeld, Ernesto and Mourão Dias, Josiane and Besse, Benjamin and Passaro, Antonio and Lee, Ki-Hyeong and Xiong, Hailin and How, Soon-Hin and Cheng, Ying and Chang, Gee-Chen and Yoshioka, Hiroshige and Thomas, Michael and Nguyen, Danny and Ou, Sai-Hong Ignatius and Mukhedkar, Sanjay and Prabhash, Kumar and D'Arcangelo, Manolo and Alatorre-Alexander, Jorge and Vázquez Limón, Juan Carlos and Alves, Sara and Stroyakovskiy, Daniil and Peregudova, Marina and Şendur, Mehmet Ali Nahit and Yazici, Ozan and Califano, Raffaele and Gutiérrez Calderón, Vanesa and de Marinis, Filippo and Kim, Sang-We and Gadgeel, Shirish M and Owen, Scott and Xie, John and Sun, Tao and Mehta, Jaydeep and Venkatasubramanian, Raja and Ennis, Mariah and Fennema, Elizabeth and Daksh, Mahesh and Roshak, Amy and Man, Julie and Knoblauch, Roland E and Bauml, Joshua M and Baig, Mahadi and Shah, Sujay and Sethi, Seema and Cho, Byoung Chul and MARIPOSA Investigators, MARIPOSA Investigators},
  title = {Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {17},
  pages = {1681--1693},
  doi = {10.1056/nejmoa2503001}
}
Kostenlos starten →